- Home
- CRDF vs LUCD Comparison
CRDF vs LUCD Comparison
Compare CRDF & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- LUCD
- Stock Information
- Founded
- CRDF 1999
- LUCD 2018
- Country
- CRDF United States
- LUCD United States
- Employees
- CRDF N/A
- LUCD N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CRDF Health Care
- LUCD Health Care
- Exchange
- CRDF Nasdaq
- LUCD Nasdaq
- Market Cap
- CRDF 169.6M
- LUCD 140.7M
- IPO Year
- CRDF N/A
- LUCD 2021
- Fundamental
- Price
- CRDF $3.21
- LUCD $1.16
- Analyst Decision
- CRDF Strong Buy
- LUCD Strong Buy
- Analyst Count
- CRDF 5
- LUCD 4
- Target Price
- CRDF $10.50
- LUCD $3.94
- AVG Volume (30 Days)
- CRDF 1.2M
- LUCD 1.2M
- Earning Date
- CRDF 08-07-2025
- LUCD 08-11-2025
- Dividend Yield
- CRDF N/A
- LUCD N/A
- EPS Growth
- CRDF N/A
- LUCD N/A
- EPS
- CRDF N/A
- LUCD N/A
- Revenue
- CRDF $587,000.00
- LUCD $4,173,000.00
- Revenue This Year
- CRDF N/A
- LUCD $91.46
- Revenue Next Year
- CRDF N/A
- LUCD $213.42
- P/E Ratio
- CRDF N/A
- LUCD N/A
- Revenue Growth
- CRDF N/A
- LUCD 39.89
- 52 Week Low
- CRDF $2.01
- LUCD $0.71
- 52 Week High
- CRDF $5.64
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- CRDF 44.28
- LUCD 42.54
- Support Level
- CRDF $2.96
- LUCD $1.13
- Resistance Level
- CRDF $3.24
- LUCD $1.34
- Average True Range (ATR)
- CRDF 0.28
- LUCD 0.07
- MACD
- CRDF -0.10
- LUCD -0.01
- Stochastic Oscillator
- CRDF 13.03
- LUCD 35.71
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.